Search
Selected Filter
Displaying 11–20 of 172 research results
-
ARVO 2019: Robot-Assisted Surgery in Clinical Trial for Retinal Disease
A video from a clinical trial of robot-assisted surgery demonstrates the potential benefits of robot-assisted subretinal injections.
-
ARVO 2019: Emerging Eloxx Molecules Show Promising Results in Usher Models
Eloxx Pharmaceuticals is developing small molecules that permit read-through of point mutations that cause Usher syndrome 1F and 2A.
-
ARVO 2019: Emerging Drug for RP Evaluated in Safety & Tolerability Study
Francois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases.
-
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Unlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
-
ARVO 2019 Highlight: RP Patients in ReNeuron’s Cell Therapy Trial Show Further Vision Improvements
The latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
-
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
The treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10
-
First Gene Therapy for Dry AMD Moves into Clinical Trial in UK
Gyroscope Therapeutics, a gene-therapy development company in the UK, has launched the first gene therapy clinical trial for the dry form of age-related macular degeneration (AMD).
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
ProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
Encouraging Vision Improvements Reported in ReNeuron's Cell-Therapy Clinical Trial
ReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.
-
Usher Syndrome Research Advances
Recent developments in research on Usher Syndrome.
